Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
© 2024. Springer Nature Limited..
Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities. For those with gastrointestinal bleeding (GIB), we summarize a general scheme for risk stratification and clinical evidence on risk reduction approaches, such as limiting the use of concomitant medications that increase the risk of GIB and the potential utility of gastrointestinal protection strategies (such as proton pump inhibitors or histamine type 2 receptor antagonists). Furthermore, we summarize the best available evidence and potential gaps in our knowledge on tailoring antithrombotic therapy in patients with active or recent GIB and in those at high risk of GIB but without active or recent GIB. Finally, we review the recommendations provided by major medical societies, highlighting the crucial role of teamwork and multidisciplinary discussions to customize the antithrombotic regimen in patients with coexisting cardiovascular and gastrointestinal diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Nature reviews. Cardiology - (2024) vom: 20. März |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1038/s41569-024-01003-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369988256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369988256 | ||
| 003 | DE-627 | ||
| 005 | 20240322001503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41569-024-01003-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369988256 | ||
| 035 | |a (NLM)38509244 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Talasaz, Azita H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. Springer Nature Limited. | ||
| 520 | |a Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities. For those with gastrointestinal bleeding (GIB), we summarize a general scheme for risk stratification and clinical evidence on risk reduction approaches, such as limiting the use of concomitant medications that increase the risk of GIB and the potential utility of gastrointestinal protection strategies (such as proton pump inhibitors or histamine type 2 receptor antagonists). Furthermore, we summarize the best available evidence and potential gaps in our knowledge on tailoring antithrombotic therapy in patients with active or recent GIB and in those at high risk of GIB but without active or recent GIB. Finally, we review the recommendations provided by major medical societies, highlighting the crucial role of teamwork and multidisciplinary discussions to customize the antithrombotic regimen in patients with coexisting cardiovascular and gastrointestinal diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Sadeghipour, Parham |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega-Paz, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Kakavand, Hessam |e verfasserin |4 aut | |
| 700 | 1 | |a Aghakouchakzadeh, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Beavers, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Fanikos, John |e verfasserin |4 aut | |
| 700 | 1 | |a Eikelboom, John W |e verfasserin |4 aut | |
| 700 | 1 | |a Siegal, Deborah M |e verfasserin |4 aut | |
| 700 | 1 | |a Monreal, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Vaduganathan, Muthiah |e verfasserin |4 aut | |
| 700 | 1 | |a Castellucci, Lana A |e verfasserin |4 aut | |
| 700 | 1 | |a Cuker, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Geoffrey D |e verfasserin |4 aut | |
| 700 | 1 | |a Connors, Jean M |e verfasserin |4 aut | |
| 700 | 1 | |a Secemsky, Eric A |e verfasserin |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 700 | 1 | |a De Caterina, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Kurlander, Jacob E |e verfasserin |4 aut | |
| 700 | 1 | |a Aminian, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Goldhaber, Samuel Z |e verfasserin |4 aut | |
| 700 | 1 | |a Moores, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Middeldorp, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Kirtane, Ajay J |e verfasserin |4 aut | |
| 700 | 1 | |a Elkind, Mitchell S V |e verfasserin |4 aut | |
| 700 | 1 | |a Angiolillo, Dominick J |e verfasserin |4 aut | |
| 700 | 1 | |a Konstantinides, Stavros |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Gregg W |e verfasserin |4 aut | |
| 700 | 1 | |a Cushman, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Krumholz, Harlan M |e verfasserin |4 aut | |
| 700 | 1 | |a Mehran, Roxana |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatt, Deepak L |e verfasserin |4 aut | |
| 700 | 1 | |a Bikdeli, Behnood |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews. Cardiology |d 2009 |g (2024) vom: 20. März |w (DE-627)NLM18770001X |x 1759-5010 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41569-024-01003-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 03 | ||